Skip to content
10-Q

Quarterly Report

ARS Pharmaceuticals, Inc. SPRY

0001193125-26-225142

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 99.3M sh
Shares Diluted Q1 2026 · Mar 31, 2026 99.3M sh
Shares Diluted Q1 2026 · Mar 31, 2025 98.06M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $91K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$44.95M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$40.74M
Long Term Debt Q1 2026 · Mar 31, 2026 $96.52M
Long Term Debt Q1 2026 · Dec 31, 2025 $96.37M
Short Term Investments Q1 2026 · Mar 31, 2026 $176.65M
Short Term Investments Q1 2026 · Dec 31, 2025 $203.67M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $24.32M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $41.32M
Stockholders Equity Q1 2026 · Mar 31, 2026 $61.31M
Stockholders Equity Q1 2026 · Dec 31, 2025 $114.26M
Stockholders Equity Q1 2026 · Mar 31, 2025 $228.97M
Stockholders Equity Q1 2026 · Dec 31, 2024 $256.8M
Current Liabilities Q1 2026 · Mar 31, 2026 $49.61M
Current Liabilities Q1 2026 · Dec 31, 2025 $39.15M
Total Liabilities Q1 2026 · Mar 31, 2026 $226.26M
Total Liabilities Q1 2026 · Dec 31, 2025 $213.39M
Current Assets Q1 2026 · Mar 31, 2026 $245.24M
Current Assets Q1 2026 · Dec 31, 2025 $284.9M
Total Assets Q1 2026 · Mar 31, 2026 $287.57M
Total Assets Q1 2026 · Dec 31, 2025 $327.65M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.61
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.35
Eps Basic Q1 2026 · Mar 31, 2026 −$0.61
Eps Basic Q1 2026 · Mar 31, 2025 −$0.35
Sga Expense Q1 2026 · Mar 31, 2026 $72.2M
Sga Expense Q1 2026 · Mar 31, 2025 $41.1M
Rd Expense Q1 2026 · Mar 31, 2026 $4.34M
Rd Expense Q1 2026 · Mar 31, 2025 $2.95M
Net Income Q1 2026 · Mar 31, 2026 −$60.62M
Net Income Q1 2026 · Mar 31, 2025 −$33.94M
Operating Income Q1 2026 · Mar 31, 2026 −$60.15M
Operating Income Q1 2026 · Mar 31, 2025 −$37.18M
Revenue Q1 2026 · Mar 31, 2026 $22.68M
Revenue Q1 2026 · Mar 31, 2025 $7.97M